Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Health Security

    Federal Select Agent Program Clarifies Requirements for Botulinum Neurotoxin Gene Constructs

    By Global Biodefense StaffMay 4, 2022
    Emerito Rodriguez, medical technologist/biosafety officer, conducts the test in BSL3 and shows results on computer screen. Rodriguez batches samples for testing on a testing plate. Photo credit: Christina Westover
    Share
    Facebook LinkedIn Reddit Email

    The Federal Select Agent Program, part of the Centers for Disease Control and Prevention Division of Select Agents and Toxins, recently posted an updated regulatory interpretation regarding constructs of botulinum neurotoxin genes in response to a stakeholder question. 

    The guidance addresses specifically the question as to which constructs containing genes encoding botulinum neurotoxin would be subject to Select Agent regulations as outlined below and in 42 CFR § 73.3(c)(2). The regulatory provision provides:

    73.3 (c) Genetic Elements, Recombinant and/or Synthetic Nucleic Acids, and Recombinant and/or Synthetic Organisms:

    (2)  Recombinant and/or Synthetic nucleic acids that encode for the toxic form(s) of any of the toxins listed in paragraph (b) of this section if the nucleic acids:

    (i) Can be expressed in vivo or in vitro, or

    (ii)  Are in a vector or recombinant host genome and can be expressed in vivo or in vitro.

    The Division of Select Agents and Toxins (DSAT) has determined the following based on the submitted questions:

    Are plasmids containing full-length botulinum neurotoxin genes without a promoter for expression of the neurotoxin gene (DNA only, cannot be expressed even in a bacterial strain) subject to the select agent regulations?

    No. Plasmids containing genes encoding the full-length botulinum neurotoxin without a promoter for expression of the neurotoxin genes are not regulated nucleic acids because the plasmids cannot be expressed in vitro or in vivo as outlined in § 73.3(c)(2).

    Are plasmids containing full-length botulinum neurotoxin genes with a promoter for expression of the neurotoxin gene (DNA only, can be expressed only in a bacterial expression strain) subject to the select agent regulations?

    Yes. Plasmids containing genes encoding the full-length botulinum neurotoxin with a promotor for expression of the neurotoxin genes are regulated nucleic acids because the plasmids can be expressed in the bacterial strain as outlined in § 73.3(c)(2).

    Are plasmids containing full-length botulinum neurotoxin genes with no promoter for expression of the neurotoxin gene in a bacterial strain subject to the select agent regulations?

    No. Plasmids containing genes encoding the full-length botulinum neurotoxin without a promoter for expression of the neurotoxin genes in a bacterial strain are not regulated nucleic acids because the plasmids cannot be expressed in vitro or in vivo as outlined in § 73.3(c)(2).

    Are plasmids containing full-length botulinum neurotoxin genes with a promoter for expression of the neurotoxin gene in a bacterial strain subject to the select agent regulations?

    Yes. Plasmids containing full-length botulinum neurotoxin genes with a promotor for expression of the neurotoxin gene in a bacterial strain are regulated nucleic acids because the plasmids can be expressed in the bacterial strain as outlined in § 73.3(c)(2).

    Source: Federal Select Agent Program. Please visit SelectAgents.gov for the latest guidance.

    Biosafety Botulinum Neurotoxin BSL-3 HHS Select Agents
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleBugSeq Awarded BARDA DRIVe Funding to Develop Next-Gen Diagnostics for Any Respiratory RNA Virus
    Next Article Biodefense Headlines – 4 May 2022

    Related Stories

    Provide Feedback on Federal DURC Biosafety Oversight of Potential Pandemic Pathogens

    September 24, 2023

    New Method Improves Quantification of Ricin in Complex Matrices

    September 20, 2023

    Field Detection of Botulinum Neurotoxin with Acoustic Wave Sensors

    September 15, 2023

    Impact of COVID-19 Pandemic on Emergency Department Use in British Columbia

    September 5, 2023
    News Scan

    Biodefense Headlines – 19 September 2023

    News Scan September 19, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include a global survey of gain-of-function research; funding of an mRNA mpox vaccine; Nipah virus outbreak in India; field detection of threat agents with acoustic…

    Upcoming Events

    Oct 3
    Virtual Event Virtual Event
    October 3 - October 5

    OneLab Summit 2023

    Oct 3
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships to Distribute, Dispense, and Administer Medical Countermeasures

    Oct 4
    Virtual Event Virtual Event
    10:00 am - 2:00 pm EDT

    Tunneling Nanotubes and Intracellular Protrusions Workshop

    Oct 12
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships for Acceptance and Uptake of Medical Countermeasures

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.